2. Academic Validation
  3. Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer

Applications of immunoPET: using 124I-anti-PSCA A11 minibody for imaging disease progression and response to therapy in mouse xenograft models of prostate cancer

  • Clin Cancer Res. 2014 Dec 15;20(24):6367-78. doi: 10.1158/1078-0432.CCR-14-1452.
Scott M Knowles 1,  Richard Tavaré 1,  Kirstin A Zettlitz 1,  Matthew M Rochefort 2,  Felix B Salazar 1,  Ziyue Karen Jiang 3,  Robert E Reiter 4,  Anna M Wu 5
Affiliations

Affiliations

  • 1 Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, California.
  • 2 Department of Surgery, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, California.
  • 3 Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, California. Department of Urology, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, California.
  • 4 Department of Urology, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, California.
  • 5 Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at the University of California-Los Angeles, Los Angeles, California. awu@mednet.ucla.edu.
PMID: 25326233 DOI: 10.1158/1078-0432.CCR-14-1452
Abstract

Purpose: Prostate stem cell antigen (PSCA) is highly expressed in local prostate cancers and prostate Cancer bone metastases and its expression correlates with Androgen Receptor activation and a poor prognosis. In this study, we investigate the potential clinical applications of immunoPET with the anti-PSCA A11 minibody, an antibody fragment optimized for use as an imaging agent. We compare A11 minibody immunoPET to (18)F-Fluoride PET bone scans for detecting prostate Cancer bone tumors and evaluate the ability of the A11 minibody to image tumor response to androgen deprivation.

Experimental design: Osteoblastic, PSCA-expressing, LAPC-9 intratibial xenografts were imaged with serial (124)I-anti-PSCA A11 minibody immunoPET and (18)F-Fluoride bone scans. Mice bearing LAPC-9 subcutaneous xenografts were treated with either vehicle or MDV-3100 and imaged with A11 minibody immunoPET/CT scans pre- and posttreatment. Ex vivo flow cytometry measured the change in PSCA expression in response to androgen deprivation.

Results: A11 minibody demonstrated improved sensitivity and specificity over (18)F-Fluoride bone scans for detecting LAPC-9 intratibial xenografts at all time points. LAPC-9 subcutaneous xenografts showed downregulation of PSCA when treated with MDV-3100 which A11 minibody immunoPET was able to detect in vivo.

Conclusions: A11 minibody immunoPET has the potential to improve the sensitivity and specificity of clinical prostate Cancer metastasis detection over bone scans, which are the current clinical standard-of-care. A11 minibody immunoPET additionally has the potential to image the activity of the androgen signaling axis in vivo which may help evaluate the clinical response to androgen deprivation and the development of castration resistance.

Figures
Products